Breaking News Instant updates and real-time market news.

MRK

Merck

$61.19

-1 (-1.61%)

07:05
12/01/16
12/01
07:05
12/01/16
07:05

Merck says FDA grants priority review to sBLA for Keytruda in relapsed cHL

Merck announced that the U.S. FDA has accepted for review the supplemental Biologics License Application for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma or for patients who have relapsed after three or more prior lines of therapy. The FDA granted Priority Review with a PDUFA, or target action, date of March 15, 2017. The sBLA will be reviewed under the FDA's Accelerated Approval program. In April 2016, KEYTRUDA was granted Breakthrough Therapy Designation by the FDA for this indication. The application is seeking approval for KEYTRUDA at a fixed dose of 200 mg administered intravenously every three weeks and is based on data from the KEYNOTE-087 and KEYNOTE-013 trials, which studied patients with refractory cHL or who had relapsed after three or more prior lines of therapy. This is the first application for regulatory approval of KEYTRUDA in a hematologic malignancy. The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including nearly 200 trials that combine KEYTRUDA with other cancer treatments. For hematologic malignancies specifically, Merck is conducting broad immuno-oncology research assessing the role of monotherapy and combination regimens with KEYTRUDA. The program includes nearly 40 ongoing studies - several of which are registration-enabling trials - across more than 20 hematologic subtypes, including leukemia, lymphomas and myeloma.

  • 01

    Dec

  • 03

    Dec

  • 08

    Mar

MRK Merck
$61.19

-1 (-1.61%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.

TODAY'S FREE FLY STORIES

SNE

Sony

$30.93

-0.31 (-0.99%)

20:43
02/26/17
02/26
20:43
02/26/17
20:43
Hot Stocks
Sony confirms 915,000 PlayStation VR global unit sales »

Sony Interactive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 10

    Mar

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

20:38
02/26/17
02/26
20:38
02/26/17
20:38
Hot Stocks
Berkshire Hathaway says paid roughly $110.17 per share for Apple stake »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

AAPL

Apple

$136.66

0.13 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

20:31
02/26/17
02/26
20:31
02/26/17
20:31
Hot Stocks
Buffett: Will be 'ready to act' on share repurchase opportunities »

Writing in Berkshire…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

20:25
02/26/17
02/26
20:25
02/26/17
20:25
Hot Stocks
Samsung teases March 29 date for next Galaxy device »

Samsung has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

SNE

Sony

$30.93

-0.31 (-0.99%)

20:14
02/26/17
02/26
20:14
02/26/17
20:14
Periodicals
Sony sells 915,000 Playstation VR units in first four months, NYT says »

Speaking in a New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 10

    Mar

AAPL

Apple

$136.66

0.13 (0.10%)

20:07
02/26/17
02/26
20:07
02/26/17
20:07
Hot Stocks
Al Gore sells 215,400 shares of Apple »

Apple board member and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

BBRY

BlackBerry

$7.08

-0.08 (-1.12%)

20:00
02/26/17
02/26
20:00
02/26/17
20:00
Hot Stocks
TCL Communication unveils 'BlackBerry KEYone' smartphone »

Smartphone manufacturer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$153.48

0.19 (0.12%)

, GD

General Dynamics

$189.63

1.33 (0.71%)

19:57
02/26/17
02/26
19:57
02/26/17
19:57
Periodicals
Trump to seek 'sharp' boost in defense spending, NYT says »

President Donald Trump…

RTN

Raytheon

$153.48

0.19 (0.12%)

GD

General Dynamics

$189.63

1.33 (0.71%)

LMT

Lockheed Martin

$266.00

1.15 (0.43%)

BA

Boeing

$177.44

0.58 (0.33%)

UTX

United Technologies

$112.46

0.37 (0.33%)

NOC

Northrop Grumman

$245.05

1.19 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMAX

IMAX

$32.75

1.6 (5.14%)

19:52
02/26/17
02/26
19:52
02/26/17
19:52
Hot Stocks
IMAX says China's Bona Film commits to 30 new IMAX theatres »

IMAX and IMAX China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 28

    Mar

  • 28

    Mar

F

Ford

$12.47

-0.09 (-0.72%)

, GM

General Motors

$36.90

-0.35 (-0.94%)

19:49
02/26/17
02/26
19:49
02/26/17
19:49
Periodicals
Chao says Trump administration reviewing autonomous car guidance, Reuters says »

Transportation Secretary…

F

Ford

$12.47

-0.09 (-0.72%)

GM

General Motors

$36.90

-0.35 (-0.94%)

TSLA

Tesla

$257.00

1.01 (0.39%)

GOOG

Alphabet

$828.64

-2.69 (-0.32%)

GOOGL

Alphabet Class A

$847.81

-3.19 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

19:35
02/26/17
02/26
19:35
02/26/17
19:35
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$75.88

-1 (-1.30%)

19:24
02/26/17
02/26
19:24
02/26/17
19:24
Periodicals
SoftBank poised to invest over $3B in WeWork, CNBC says »

SoftBank is nearing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRPN

Groupon

$4.47

0.05 (1.13%)

19:22
02/26/17
02/26
19:22
02/26/17
19:22
Recommendations
Groupon analyst commentary  »

Piper believes Groupon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ALSN

Allison Transmission

$36.79

0.24 (0.66%)

, F

Ford

$12.47

-0.09 (-0.72%)

19:07
02/26/17
02/26
19:07
02/26/17
19:07
Downgrade
Allison Transmission, Ford rating change  »

Allison Transmission…

ALSN

Allison Transmission

$36.79

0.24 (0.66%)

F

Ford

$12.47

-0.09 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 11

    May

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

18:39
02/26/17
02/26
18:39
02/26/17
18:39
Hot Stocks
Berkshire Hathaway's Buffett: Expect normalized earning power to grow every year »

Writing in Berkshire…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

18:26
02/26/17
02/26
18:26
02/26/17
18:26
Hot Stocks
Deutsche Boerse sees European Commission merger decision by end of March »

Deutsche Boerse issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MESO

Mesoblast

$6.40

-0.14 (-2.14%)

18:23
02/26/17
02/26
18:23
02/26/17
18:23
Hot Stocks
Mesoblast outlines expected 2017 milestones »

Mesoblast stated that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Apr

LIOX

Lionbridge

16:58
02/26/17
02/26
16:58
02/26/17
16:58
Conference/Events
Lionbridge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$37.89

0.24 (0.64%)

, CMCSK

Comcast

16:54
02/26/17
02/26
16:54
02/26/17
16:54
Hot Stocks
Box Office Battle: Comedy horror 'Get Out' thrills in $31M opening »

Comcast's (CMCSA)…

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

TWX

Time Warner

$97.28

0.6225 (0.64%)

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

DIS

Disney

$110.32

0.59 (0.54%)

FOX

21st Century Fox

$30.23

0.23 (0.77%)

FOXA

21st Century Fox

$30.61

0.27 (0.89%)

VIA

Viacom

VIAB

Viacom

$43.89

0.03 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

WAT

Waters

$156.40

1.51 (0.97%)

16:38
02/26/17
02/26
16:38
02/26/17
16:38
Conference/Events
Waters to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 01

    Apr

CR

Crane

$73.21

1.18 (1.64%)

16:36
02/26/17
02/26
16:36
02/26/17
16:36
Conference/Events
Crane to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

16:34
02/26/17
02/26
16:34
02/26/17
16:34
Hot Stocks
LSE rejects European Commission merger demand, says unlikely to approve deal »

London Stock Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCO

Brink's

$52.00

0.7 (1.36%)

16:33
02/26/17
02/26
16:33
02/26/17
16:33
Conference/Events
Brink's to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

XOM

Exxon Mobil

$81.08

-0.7 (-0.86%)

16:28
02/26/17
02/26
16:28
02/26/17
16:28
Conference/Events
Exxon Mobil to host analyst meeting with a conference call hook-up »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.84

0.2 (3.55%)

16:22
02/26/17
02/26
16:22
02/26/17
16:22
Conference/Events
TherapeuticsMD to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 21

    Mar

  • 07

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.